Injectable contraceptive use and genital ulcer disease during the early phase of HIV-1 infection increase plasma virus load in women.

We examined the association between host factors present near the time of human immunodeficiency virus type 1 (HIV-1) acquisition and subsequent virus loads, in a prospective cohort study of women in Mombasa, Kenya. Women were prospectively followed monthly before HIV-1 infection. One hundred sixty-one commercial sex workers who became infected with HIV-1 were followed for a median of 34 months, and 991 plasma samples collected > or =4 months after infection were tested for HIV-1 RNA. The median virus set point at 4 months after infection was 4.46 log10 copies/mL, and the average virus load increase during subsequent follow-up was 0.0094 log10 copies/mL/month. In a multivariate analysis that controlled for sexual behavior, the use of the injectable contraceptive depot medroxyprogesterone acetate (DMPA) at the time of HIV-1 infection was associated with a higher virus set point, and the presence of genital ulcer disease (GUD) during the early phase of HIV-1 infection was associated with greater change in virus load during follow-up. These findings suggest that, in women, the use of DMPA and the presence of GUD during the early phase of HIV-1 infection may influence the natural course of infection.

[1]  J. S. Hunt,et al.  Hormonal Regulation of Uterine Macrophages , 1998, Developmental immunology.

[2]  P. Hartigan,et al.  Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. , 1996, The New England journal of medicine.

[3]  T. Pardthaisong,et al.  RETURN OF FERTILITY AFTER DISCONTINUATION OF DEPOT MEDROXYPROGESTERONE ACETATE AND INTRA-UTERINE DEVICES IN NORTHERN THAILAND , 1980, The Lancet.

[4]  A. Wald,et al.  Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. , 2002, The Journal of infectious diseases.

[5]  G. Satten,et al.  Time course of detection of viral and serologic markers preceding human immunodeficiency virus type 1 seroconversion: implications for screening of blood and tissue donors , 1995, Transfusion.

[6]  John W. Mellors,et al.  Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma , 1996, Science.

[7]  J. Margolick,et al.  Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users: plasma viral load and CD4+ cell count. , 1998, JAMA.

[8]  J. Mellors,et al.  Quantitation of HIV-1 RNA in Plasma Predicts Outcome after Seroconversion , 1995, Annals of Internal Medicine.

[9]  J. Baeten,et al.  Identification of modifiable factors that affect the genetic diversity of the transmitted HIV-1 population , 2004, AIDS.

[10]  Lawrence Corey,et al.  Biological and Virologic Characteristics of Primary HIV Infection , 1998, Annals of Internal Medicine.

[11]  T. Schacker,et al.  Clinical and Epidemiologic Features of Primary HIV Infection , 1996, Annals of Internal Medicine.

[12]  M A Krohn,et al.  Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation , 1991, Journal of clinical microbiology.

[13]  C. Poole,et al.  Gender Difference in HIV RNA Levels: A Meta‐Analysis of Published Studies , 2002, Journal of acquired immune deficiency syndromes.

[14]  H. Schuitemaker,et al.  Association between CCR5 Genotype and the Clinical Course of HIV-1 Infection , 1997, Annals of Internal Medicine.

[15]  T. Holford,et al.  Conception delay after oral contraceptive use: the effect of estrogen dose. , 1990, Fertility and sterility.

[16]  J. Margolick,et al.  Virologic and serologic markers of rapid progression to AIDS after HIV-1 seroconversion. , 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[17]  R. Salamon,et al.  Clinical and Biological Evolution of HIV‐1 Seroconverters in Abidjan, Côte d’Ivoire, 1997‐2000 , 2002, Journal of acquired immune deficiency syndromes.

[18]  L. Mole,et al.  The impact of active herpes simplex virus infection on human immunodeficiency virus load. , 1997, The Journal of infectious diseases.

[19]  N. Nagelkerke,et al.  Rapid progression to disease in African sex workers with human immunodeficiency virus type 1 infection. , 1995, The Journal of infectious diseases.

[20]  S. Rowland-Jones,et al.  CCR5 promoter polymorphisms in a Kenyan perinatal human immunodeficiency virus type 1 cohort: association with increased 2-year maternal mortality. , 2001, The Journal of infectious diseases.

[21]  Douglas D. Richman,et al.  Viral Dynamics of Acute HIV-1 Infection , 1999, The Journal of experimental medicine.

[22]  J. Phair,et al.  Acquired immune deficiency syndrome occurring within 5 years of infection with human immunodeficiency virus type-1: the Multicenter AIDS Cohort Study. , 1992, Journal of acquired immune deficiency syndromes.

[23]  F. Gotch,et al.  Oral contraceptive use induces upregulation of the CCR5 chemokine receptor on CD4(+) T cells in the cervical epithelium of healthy women. , 2002, Journal of reproductive immunology.

[24]  J J Goedert,et al.  Natural history of HIV-1 cell-free viremia. , 1995, JAMA.

[25]  L. Jagodzinski,et al.  Evaluation of Performance of the Gen-Probe Human Immunodeficiency Virus Type 1 Viral Load Assay Using Primary Subtype A, C, and D Isolates from Kenya , 2000, Journal of Clinical Microbiology.

[26]  N. Sewankambo,et al.  Hormonal contraceptive use and HIV-1 infection in a population-based cohort in Rakai, Uganda , 2003, AIDS.

[27]  D. Ho,et al.  Viral Counts Count in HIV Infection , 1996, Science.

[28]  J. Albert,et al.  Plasma viral load in HIV-1 and HIV-2 singly and dually infected individuals in Guinea-Bissau, West Africa: significantly lower plasma virus set point in HIV-2 infection than in HIV-1 infection. , 2000, Archives of internal medicine.

[29]  M. Moriuchi,et al.  In vitro reactivation of HIV-1 by stimulation with herpes simplex virus infection. , 2002, Sexually transmitted diseases.

[30]  J. Andersson,et al.  Repertoire of chemokine receptor expression in the female genital tract: implications for human immunodeficiency virus transmission. , 1998, The American journal of pathology.

[31]  J. Baeten,et al.  Virus load during primary Human Immunodeficiency Virus (HIV) type 1 infection is related to the severity of acute HIV illness in Kenyan women. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  S. Straus,et al.  Herpes simplex virus infection induces replication of human immunodeficiency virus type 1. , 2000, Virology.

[33]  J. Baeten,et al.  Hormonal contraception and risk of sexually transmitted disease acquisition: results from a prospective study. , 2001, American journal of obstetrics and gynecology.

[34]  D. Katzenstein,et al.  Detection and quantification of human immunodeficiency virus RNA in patient serum by use of the polymerase chain reaction. , 1991, The Journal of infectious diseases.

[35]  R. Brookmeyer,et al.  Rapid disease progression in human immunodeficiency virus type 1-infected seroconverters in India. , 2002, AIDS research and human retroviruses.

[36]  B. Richardson,et al.  Hormonal contraception, sexually transmitted diseases, and risk of heterosexual transmission of human immunodeficiency virus type 1. , 1998, The Journal of infectious diseases.

[37]  J. Changalucha,et al.  Herpes simplex virus type 2 infection increases HIV incidence: a prospective study in rural Tanzania , 2002, AIDS.

[38]  D. B. Anderson,et al.  Emerging cytopathic and antigenic simian immunodeficiency virus variants influence AIDS progression , 1999, Nature Medicine.

[39]  B. Walker,et al.  Acute human immunodeficiency virus type 1 infection. , 1998, The New England journal of medicine.

[40]  J. Goedert,et al.  Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. , 1996, JAMA.

[41]  A. Fauci,et al.  Frequent detection of HIV-1-specific mRNAs in infected individuals suggests ongoing active viral expression in all stages of disease. , 1991, AIDS research and human retroviruses.

[42]  D. Cooper,et al.  Patterns of viral dynamics during primary human immunodeficiency virus type 1 infection. The Sydney Primary HIV Infection Study Group. , 1998, The Journal of infectious diseases.

[43]  R H Lyles,et al.  Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. , 2000, The Journal of infectious diseases.

[44]  D. Katzenstein,et al.  Detection and Qualification of Human Immunodeficiency Virus RNA in Patient Serum by Use of the Polymerase Chain Reaction , 1991 .

[45]  D. Ho,et al.  Progesterone implants enhance SIV vaginal transmission and early virus load , 1996, Nature Medicine.

[46]  L A Kalish,et al.  The relative value of CD4 cell count and quantitative HIV-1 RNA in predicting survival in HIV-1-infected women: results of the women's interagency HIV study. , 1999, AIDS.

[47]  J. Zeh,et al.  Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression. , 2002, The Journal of infectious diseases.

[48]  S. Eholie,et al.  Distribution of HIV-1 plasma RNA viral load and CD4 + T-cell counts among HIV-infected Africans evaluated for antiretroviral therapy. , 2001, Journal of acquired immune deficiency syndromes.

[49]  A. Ashkar,et al.  Progesterone Increases Susceptibility and Decreases Immune Responses to Genital Herpes Infection , 2003, Journal of Virology.

[50]  B. Chohan,et al.  Cervical shedding of herpes simplex virus in human immunodeficiency virus-infected women: effects of hormonal contraception, pregnancy, and vitamin A deficiency. , 2000, The Journal of infectious diseases.